-transparent.png){kind=logo}
Tenoxicam 20 mg OD was compared with piroxicam 20 mg OD for patients with rheumatoid arthritis (RA). One hundred and two patients from 5 centers were enrolled: 51 in the tenoxicam group and 51 in the piroxicam group. Evaluation of the primary efficacy variables demonstrated no difference in efficacy between treatment groups. The overall incidence of adverse clinical/laboratory experiences was similar between treatment groups. Six patients discontinued the study because of gastrointestinal intolerance, 3 from each treatment group. Our study demonstrates that tenoxicam 20 mg OD and piroxicam 20 mg OD have similar efficacy and safety in patients with active RA.
Related Publications
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
January 1989,
Scandinavian journal of rheumatology. Supplement,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
September 1989,
The British journal of clinical practice,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
January 1981,
European journal of rheumatology and inflammation,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
January 1988,
Terapevticheskii arkhiv,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
January 1987,
European journal of rheumatology and inflammation,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
January 1993,
Clinical therapeutics,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
January 1987,
European journal of rheumatology and inflammation,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
May 1982,
The New Zealand medical journal,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
February 1985,
Seminars in arthritis and rheumatism,
M Atkinson, and
V Khanna, and
H Ménard, and
A S Russel, and
H Tannenbaum
June 1990,
Vnitrni lekarstvi,
